PARK1
MCID: PRK031
MIFTS: 51

Parkinson Disease 1 (PARK1) malady

Categories: Genetic diseases, Neuronal diseases, Mental diseases, Rare diseases, Metabolic diseases

Aliases & Classifications for Parkinson Disease 1

Aliases & Descriptions for Parkinson Disease 1:

Name: Parkinson Disease 1 54 29 13
Parkinson Disease 1, Autosomal Dominant 66 69
Atypical Parkinson Disease 66 69
Autosomal Dominant Parkinson Disease 1 12
Parkinson Disease Autosomal Dominant 1 66
Parkinson Disease, Familial, Type 1 69
Parkinson Disease Familial Type 1 66
Lewy Body Parkinsonism 66
Park1 66

Characteristics:

HPO:

32
parkinson disease 1:
Inheritance autosomal dominant inheritance
Onset and clinical course progressive insidious onset


Classifications:



External Ids:

OMIM 54 168601
Disease Ontology 12 DOID:0060367
MeSH 42 D010300

Summaries for Parkinson Disease 1

UniProtKB/Swiss-Prot : 66 Parkinson disease 1, autosomal dominant: A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.

MalaCards based summary : Parkinson Disease 1, also known as parkinson disease 1, autosomal dominant, is related to kufor-rakeb syndrome and parkinson disease 4, and has symptoms including myoclonus, dystonia and bradykinesia. An important gene associated with Parkinson Disease 1 is SNCA (Synuclein Alpha), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Chks in Checkpoint Regulation. The drugs Rasagiline and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A Parkinson's disease that has material basis in mutation in the alpha-synuclein (SNCA) gene on chromosome 4q22.1.

OMIM : 54 Parkinson disease is the second most common neurogenic disorder after Alzheimer disease (AD; 104300), affecting... (168601) more...

Related Diseases for Parkinson Disease 1

Diseases in the Parkinson Disease, Late-Onset family:

Parkinson Disease 7, Autosomal Recessive Early-Onset Parkinson Disease 6, Early Onset
Parkinson Disease 19, Juvenile-Onset Parkinson Disease 10
Parkinson Disease 16 Parkinson Disease 13
Parkinson Disease 11 Parkinson Disease 21
Parkinson Disease 18 Parkinson Disease 5
Parkinson Disease 4 Parkinson Disease 1
Parkinson Disease, Juvenile, Type 2 Parkinson Disease 8
Parkinson Disease 17 Parkinson Disease 20, Early-Onset
Parkinson Disease 15, Autosomal Recessive Parkinson Disease 14, Autosomal Recessive
Parkinson Disease 12 Juvenile Onset Parkinson Disease 19a
Juvenile-Onset Parkinson Disease Early-Onset Parkinson Disease
Lrrk2-Related Parkinson Disease Parkinson Disease Type 3
Parkinson Disease Type 9 Dnajc6-Related Parkinson Disease
Eif4g1-Related Parkinson Disease Gigyf2-Related Parkinson Disease
Pla2g6-Related Parkinson Disease Synj1-Related Parkinson Disease
Fbxo7-Related Parkinson Disease Htra2-Related Parkinson Disease
Park7-Related Parkinson Disease Snca-Related Parkinson Disease
Vps35-Related Parkinson Disease Hereditary Late-Onset Parkinson Disease
Parkinson Disease 22 Parkinson Disease 23, Autosomal Recessive, Early Onset

Diseases related to Parkinson Disease 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 32)
id Related Disease Score Top Affiliating Genes
1 kufor-rakeb syndrome 31.3 PARK7 PINK1
2 parkinson disease 4 11.3
3 parkinson disease type 3 11.1
4 snca-related parkinson disease 11.1
5 parkinson disease, late-onset 11.1
6 riedel's fibrosing thyroiditis 10.1 MAOB SNCA
7 pythiosis 10.1 MAOB SNCA
8 autism 19 10.1 MAOB SNCA
9 mitochondrial dna depletion syndrome 3 10.0 SLC18A2 SNCA
10 parkinson disease 6, early onset 10.0 PARK7 PINK1
11 nephrogenic adenoma of the urethra 10.0 MAOB SLC18A2 SNCA
12 ovarian mucinous adenocarcinoma 10.0 MAOB SLC18A2 SNCA
13 cerebral atrophy 10.0 SNCA UCHL1
14 preeclampsia/eclampsia 5 9.9 MAOB SLC18A2 SNCA
15 ceroid lipofuscinosis, neuronal, 1 9.9 PARK7 PINK1 SNCA
16 lethal congenital contracture syndrome 8 9.9 PARK7 PINK1 SNCA
17 spink1-related hereditary pancreatitis 9.9 PARK7 SNCA SNCAIP
18 thrombosis 9.9 PARK7 PINK1 SNCA
19 klippel-feil syndrome 4, autosomal recessive, with myopathy and facial dysmorphism 9.9 PARK7 PINK1 SNCA
20 hypoproteinemia, hypercatabolic 9.9 PARK7 PINK1 SNCA
21 meier-gorlin syndrome 5 9.9 PARK7 SNCA
22 epithelioid type angiomyolipoma 9.8 MAOB PINK1 SLC18A2 SNCA
23 dementia, lewy body 9.7
24 dementia 9.7
25 plekhm1-related autosomal recessive osteopetrosis 9.7 PARK7 SNCA UCHL1
26 substance-induced psychosis 9.7 MAOB PARK7 PINK1 SNCA
27 cavernous hemangioma 9.7 PARK7 PINK1 SLC18A2 SNCA
28 trichothiodystrophy 3, photosensitive 9.6 PARK7 PINK1 SNCA UCHL1
29 coenzyme q10 deficiency, primary, 1 9.6 MAOB PARK7 SLC18A2 SNCA SNCAIP
30 gallbladder adenoma 9.4 MAOB PARK7 PINK1 SLC18A2 SNCA SNCAIP
31 multiple system atrophy 9.1 MAOB PARK7 PINK1 SLC18A2 SNCA SNCAIP
32 hemochromatosis, type 2a 9.0 MAOB PARK7 PINK1 SLC18A2 SNCA SNCAIP

Graphical network of the top 20 diseases related to Parkinson Disease 1:



Diseases related to Parkinson Disease 1

Symptoms & Phenotypes for Parkinson Disease 1

Symptoms by clinical synopsis from OMIM:

168601

Clinical features from OMIM:

168601

Human phenotypes related to Parkinson Disease 1:

32 (show all 15)
id Description HPO Frequency HPO Source Accession
1 myoclonus 32 HP:0001336
2 dystonia 32 HP:0001332
3 bradykinesia 32 HP:0002067
4 depression 32 HP:0000716
5 dysarthria 32 HP:0001260
6 dysphagia 32 HP:0002015
7 sleep disturbance 32 HP:0002360
8 rigidity 32 HP:0002063
9 mental deterioration 32 HP:0001268
10 hypokinesia 32 HP:0002375
11 parkinsonism 32 HP:0001300
12 postural instability 32 HP:0002172
13 urinary urgency 32 HP:0000012
14 shuffling gait 32 HP:0002362
15 resting tremor 32 HP:0002322

UMLS symptoms related to Parkinson Disease 1:


muscle rigidity, myoclonus, sleep disturbances, bradykinesia

MGI Mouse Phenotypes related to Parkinson Disease 1:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.73 MAOB PARK7 PINK1 SLC18A2 SNCA UCHL1
2 homeostasis/metabolism MP:0005376 9.63 PINK1 SLC18A2 SNCA UCHL1 MAOB PARK7
3 nervous system MP:0003631 9.43 MAOB PARK7 PINK1 SLC18A2 SNCA UCHL1
4 taste/olfaction MP:0005394 8.8 PINK1 SLC18A2 SNCA

Drugs & Therapeutics for Parkinson Disease 1

Drugs for Parkinson Disease 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 458)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rasagiline Approved Phase 4,Phase 3,Phase 2,Phase 1 136236-51-6 3052776
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
3
Pramipexole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104632-26-0 59868 119570
4
Ropinirole Approved, Investigational Phase 4,Phase 3,Phase 1 91374-20-8, 91374-21-9 5095 497540
5
Donepezil Approved Phase 4,Phase 2,Phase 1 120014-06-4 3152
6
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-92-7 6047
7
Amantadine Approved Phase 4,Phase 3,Phase 2,Phase 1 768-94-5 2130
8
Bromocriptine Approved, Investigational Phase 4,Phase 3,Phase 2 25614-03-3 31101
9
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
10
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
11
Carbidopa Approved Phase 4,Phase 3,Phase 2,Phase 1 28860-95-9 34359 38101
12
Varenicline Approved, Investigational Phase 4,Phase 2 249296-44-4 5310966
13 Piracetam Approved Phase 4,Phase 2 7491-74-9
14
Norepinephrine Approved Phase 4,Phase 1,Phase 2 51-41-2 439260
15
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3 76631-46-4, 113775-47-6 68602 5311068 56032
16
Entacapone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130929-57-6 5281081
17
Methylphenidate Approved, Investigational Phase 4,Early Phase 1 113-45-1 4158
18
Apomorphine Approved, Investigational Phase 4,Phase 3,Phase 2 41372-20-7, 58-00-4 6005
19
Trimethobenzamide Approved Phase 4,Phase 1 138-56-7 5577
20
Memantine Approved, Investigational Phase 4,Phase 2 19982-08-2 4054
21
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 26757 5195
22
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
23
Cabergoline Approved Phase 4,Phase 3 81409-90-7 54746
24
Midodrine Approved Phase 4,Phase 1 133163-28-7, 42794-76-3 4195
25
Armodafinil Approved, Investigational Phase 4,Phase 2,Early Phase 1 112111-43-0
26
Modafinil Approved, Investigational Phase 4,Phase 2,Early Phase 1 68693-11-8 4236
27
Atenolol Approved Phase 4 29122-68-7 2249
28
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
29
Trandolapril Approved Phase 4 87679-37-6 5484727
30
Verapamil Approved Phase 4 52-53-9 2520
31
Droxidopa Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 23651-95-8 443940
32
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2 123441-03-2 77991
33
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
34
Suvorexant Approved Phase 4 1030377-33-3
35
Mirabegron Approved Phase 4 223673-61-8
36
Amitriptyline Approved Phase 4 50-48-6 2160
37
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
38
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
39
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
40
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
41
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
42
Propranolol Approved, Investigational Phase 4 525-66-6 4946
43
Rizatriptan Approved Phase 4 145202-66-0, 144034-80-0 5078
44
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
45
Topiramate Approved Phase 4 97240-79-4 5284627
46
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
47
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
48
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 2 67-97-0 6221 10883523 5280795
49
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2 50-14-6 5280793
50
Clopidogrel Approved, Nutraceutical Phase 4 120202-66-6, 113665-84-2 60606

Interventional clinical trials:

(show top 50) (show all 1058)
id Name Status NCT ID Phase
1 Emotion, Mood and Executive Function in Parkinson`s Disease (PD) Unknown status NCT01385735 Phase 4
2 The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease Unknown status NCT00696215 Phase 4
3 A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients Unknown status NCT01007630 Phase 4
4 Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study Unknown status NCT01765257 Phase 4
5 Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID) Unknown status NCT01515774 Phase 4
6 The Effect of Donepezil on Gait and Balance in Parkinson's Disease Unknown status NCT01521117 Phase 4
7 Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients Unknown status NCT01780467 Phase 4
8 The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy Unknown status NCT01313819 Phase 4
9 Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease Unknown status NCT01673724 Phase 4
10 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4
11 Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson's Disease Unknown status NCT00354133 Phase 4
12 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain Completed NCT01744496 Phase 4
13 Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy Completed NCT01782222 Phase 4
14 Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease Completed NCT01723228 Phase 4
15 Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease Completed NCT00437125 Phase 4
16 Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease Completed NCT01049984 Phase 4
17 Olfaction in Patients With Parkinson's Disease Following Treatment With Rasagiline Completed NCT00902941 Phase 4
18 A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery Completed NCT00594464 Phase 4
19 D-serine Adjuvant Treatment for Parkinson's Disease Completed NCT00215904 Phase 4
20 Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity Measured Through Implanted Stimulators Completed NCT02256319 Phase 4
21 Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms Completed NCT00297778 Phase 4
22 A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy Completed NCT01497652 Phase 4
23 A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease Completed NCT01711866 Phase 4
24 Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors Completed NCT00906828 Phase 4
25 Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II) Completed NCT00914095 Phase 4
26 Bradykinesia Subscale Administered Alone Versus Regular Administration: Psychometric Properties Completed NCT00932581 Phase 4
27 Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease Completed NCT01313845 Phase 4
28 Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease Completed NCT01168596 Phase 4
29 The Effect of Rasagiline on Cognition in Parkinson's Disease Completed NCT01382342 Phase 4
30 Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment Completed NCT00489255 Phase 4
31 Study of Memantine for Gait Disorders And Attention Deficit In Parkinson's Disease Completed NCT01108029 Phase 4
32 Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease Completed NCT00526630 Phase 4
33 Profile of Depressive Symptoms in Parkinsons Disease Completed NCT00349310 Phase 4
34 Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients Completed NCT01523301 Phase 4
35 Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms Completed NCT01300819 Phase 4
36 Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists Completed NCT00443872 Phase 4
37 Levodopa Benserazide Generic Formulation Versus the Originator Completed NCT02741947 Phase 4
38 Study to Evaluate Initiation of Stalevo in Early Wearing-off Completed NCT00462007 Phase 4
39 Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease Completed NCT00646204 Phase 4
40 Dopaminergic Modulation of Declarative Memory Completed NCT03151460 Phase 4
41 Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) Completed NCT01770145 Phase 4
42 Donepezil to Treat Dementia in Parkinson's Disease Completed NCT00030979 Phase 4
43 Stalevo in Early Wearing-Off Patients Completed NCT00125567 Phase 4
44 Motor Response to Sildenafil in PD Completed NCT01941732 Phase 4
45 A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease Completed NCT00399477 Phase 4
46 Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease Completed NCT01032486 Phase 4
47 Rasagiline and Apathy in Parkinson's Disease Completed NCT00755027 Phase 4
48 Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease Completed NCT00095810 Phase 4
49 Long-Term Effects of Amantadine in Parkinsonian (AMANDYSK) Completed NCT00632762 Phase 4
50 Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease Completed NCT00219284 Phase 4

Search NIH Clinical Center for Parkinson Disease 1

Genetic Tests for Parkinson Disease 1

Genetic tests related to Parkinson Disease 1:

id Genetic test Affiliating Genes
1 Parkinson Disease 1 29

Anatomical Context for Parkinson Disease 1

MalaCards organs/tissues related to Parkinson Disease 1:

39
Brain

Publications for Parkinson Disease 1

Variations for Parkinson Disease 1

UniProtKB/Swiss-Prot genetic disease variations for Parkinson Disease 1:

66
id Symbol AA change Variation ID SNP ID
1 SNCA p.Ala53Thr VAR_007454 rs104893877
2 SNCA p.Ala30Pro VAR_007957 rs104893878
3 SNCA p.Glu46Lys VAR_022703 rs104893875
4 SNCA p.His50Gln VAR_070171 rs201106962

ClinVar genetic disease variations for Parkinson Disease 1:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 SNCA NM_000345.3(SNCA): c.157G> A (p.Ala53Thr) single nucleotide variant Pathogenic rs104893877 GRCh37 Chromosome 4, 90749300: 90749300
2 SNCA NM_000345.3(SNCA): c.88G> C (p.Ala30Pro) single nucleotide variant Pathogenic rs104893878 GRCh37 Chromosome 4, 90756731: 90756731
3 SNCA SNCA, DUPLICATION duplication Pathogenic
4 SNCA NM_000345.3(SNCA): c.152G> A (p.Gly51Asp) single nucleotide variant Pathogenic rs431905511 GRCh37 Chromosome 4, 90749305: 90749305

Expression for Parkinson Disease 1

Search GEO for disease gene expression data for Parkinson Disease 1.

Pathways for Parkinson Disease 1

GO Terms for Parkinson Disease 1

Cellular components related to Parkinson Disease 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.43 SNCA SNCAIP UCHL1
2 cell body GO:0044297 9.37 PARK7 PINK1
3 mitochondrial intermembrane space GO:0005758 9.32 PARK7 PINK1
4 mitochondrial respiratory chain complex I GO:0005747 9.16 PARK7 SNCA
5 synaptic vesicle GO:0008021 9.13 SLC18A2 SNCA SNCAIP
6 axon GO:0030424 8.92 PARK7 PINK1 SNCA UCHL1

Biological processes related to Parkinson Disease 1 according to GeneCards Suite gene sharing:

(show all 21)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.77 PARK7 PINK1 SNCA
2 negative regulation of neuron apoptotic process GO:0043524 9.61 PARK7 PINK1 SNCA
3 mitochondrion organization GO:0007005 9.59 PARK7 PINK1
4 positive regulation of protein kinase B signaling GO:0051897 9.58 PARK7 PINK1
5 negative regulation of protein phosphorylation GO:0001933 9.58 PARK7 SNCA
6 adult locomotory behavior GO:0008344 9.57 PARK7 SNCA
7 negative regulation of neuron death GO:1901215 9.56 PARK7 SNCA
8 regulation of mitochondrial membrane potential GO:0051881 9.55 PARK7 PINK1
9 activation of protein kinase B activity GO:0032148 9.54 PARK7 PINK1
10 cellular response to oxidative stress GO:0034599 9.54 PARK7 PINK1 SNCA
11 regulation of neuron apoptotic process GO:0043523 9.52 PARK7 PINK1
12 regulation of reactive oxygen species metabolic process GO:2000377 9.51 PINK1 SNCA
13 synaptic transmission, dopaminergic GO:0001963 9.49 PARK7 SNCA
14 regulation of neurotransmitter secretion GO:0046928 9.48 SNCA SNCAIP
15 dopamine metabolic process GO:0042417 9.46 SNCA SNCAIP
16 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.43 PARK7 PINK1 SNCA
17 negative regulation of oxidative stress-induced neuron death GO:1903204 9.4 PARK7 PINK1
18 dopamine uptake involved in synaptic transmission GO:0051583 9.32 PARK7 SNCA
19 negative regulation of oxidative stress-induced cell death GO:1903202 9.16 PARK7 PINK1
20 negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway GO:1903384 8.96 PARK7 PINK1
21 positive regulation of mitochondrial electron transport, NADH to ubiquinone GO:1902958 8.62 PARK7 PINK1

Molecular functions related to Parkinson Disease 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 copper ion binding GO:0005507 9.16 PARK7 SNCA
2 ubiquitin protein ligase binding GO:0031625 9.13 PINK1 SNCAIP UCHL1
3 cuprous ion binding GO:1903136 8.62 PARK7 SNCA

Sources for Parkinson Disease 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....